Clinical Stage CAR-T for AL Amyloidosis and Select Immune-Mediated Diseases

ImmixBio Releases and Ships Scaled-Up GMP Batches of IMX-110 for Clinical Trial Patient Dosing

LOS ANGELES, CA, Dec. 12, 2022 — Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx)TM targeting oncology and immuno-dysregulated diseases, today announced that it has completed release testing and shipped Good Manufacturing Practice (“GMP”) process manufactured batches of IMX-110 for clinical trial patient dosing. IMX-110 was […]